Calidi Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.3M
- Price
- $1.34
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 58.9K
About
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Quick stats
Shares outstanding2.4M
Computed float18.4M
Float / shares753.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001855485
Websitehttps://calidibio.com
AI Summary
AI-generated1/20
standardmixedearnings
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Calidi Biotherapeutics received positive pre-IND feedback from the FDA for CLD-401, aligning on the development strategy and targeting first patient dosing in Q1 2027, and presented new preclinical data for CLD-501 at ASCO.
The company reported a Q2 net loss of $4.2 million with cash and restricted cash totaling $4.3 million as of June 30, while reducing general and administrative expenses by 48% year-over-year to extend runway.
Dr. Corsee Sanders, a former executive at Genentech/Roche and Celgene, was appointed to the Board of Directors.
Red flags
- Cash balance of $4.3M vs quarterly burn of $4.2M implies less than one quarter of runway
- 1-for-16 reverse stock split completed in July 2026 signals listing compliance concerns